New research reveals how exercise transforms muscles into communication hubs that release beneficial molecules throughout the ...

Joseph Jacob, MD, discusses the promising impact of TAR-200.

Group Captain Shubhanshu Shukla is conducting vital microgravity research aboard the ISS as part of the Axiom-4 mission. He's ...

Ferring Pharmaceuticals officially opened doors to its state-of-the-art gene therapy manufacturing facility in Parsippany ...

Targeted Oncology connects oncology professionals with updates on immunotherapy, biomarkers, cancer pathways, and targeted ...

May 28, 2025 To assess whether the distribution of concomitant carcinoma in situ (CIS; unifocal or multifocal) with papillary non-muscle-invasive bladder cancer (NMIBC) impacts the risk of progression ...

With respect to clinical activity observed in the trial, among evaluable patients who received UGN-301, 46% (6 of 13) of those with Ta/T1 disease and 33% (2 of 6) of those with carcinoma in situ ...

The contralateral side contained no defect. Animal gait, in situ muscle force testing, H&E, Mason’s trichrome, and immunostaining for Pax7, nicotinic acetylcholine receptor-γ and –ε (NAChR-γ and NAChR ...

CULVER CITY, CA, USA I January 27, 2025 I ImmunityBio, Inc. (NASDAQ: IBRX), a leading immunotherapy company, today announced the European Medicines Agency (EMA) has accepted for review and begun ...

Submission is based on the ongoing QUILT 3.032 study in which 100 patients with Bacillus Calmette-Guérin (BCG)-unresponsive non-muscle invasive bladder cancer with carcinoma in situ (NMIBC CIS ...

Marketing authorization application for BCG Unresponsive Non-Muscle Invasive Bladder Cancer (NMIBC) with Carcinoma in situ (CIS) submitted to European Medicines Agency (EMA) in December 2024 and ...